Glucagen Hypokit

Glucagen Hypokit is a prescription glucagon product marketed in the European Union. The active ingredient is glucagon, a peptide hormone, supplied in an injectable kit; the specific strength and dosage form are not disclosed in the public label. Glucagon acts as an antihypoglycemic agent and is administered by intramuscular, intravenous, or subcutaneous injection to rapidly increase blood glucose in emergency situations for patients in clinical practice.

Glucagen Hypokit is indicated for the treatment of severe hypoglycemia when rapid glucose elevation is required.

- Emergency treatment of insulin‑induced hypoglycemia in adults. - Management of hypoglycemia in children when oral glucose is not feasible. - Use in patients with adrenal insufficiency experiencing hypoglycemic episodes. - Administration by trained personnel in hospital, ambulance, or home settings.

Glucagen Hypokit may cause a range of adverse reactions; most are mild and transient, while rare events can be serious.

Common: - Nausea or vomiting. - Flushing or warmth at the injection site. - Headache. - Transient rise in blood pressure. - Dizziness. - Tremor. - Local pain or bruising at injection site.

Serious: - Allergic reactions such as rash, urticaria, or anaphylaxis. - Severe hyperglycemia requiring medical intervention. - Cardiovascular events such as arrhythmia in susceptible patients. - Hypersensitivity reactions including angioedema.

When using Glucagen Hypokit, clinicians should consider several precautions to ensure safe and effective treatment of hypoglycemia.

- Verify the diagnosis of severe hypoglycemia before administration. - Use only when intravenous glucose is unavailable or delayed. - Avoid repeated dosing within a short interval; monitor blood glucose closely. - Adjust dose in patients with known glucagon antibody presence. - Exercise caution in patients with pheochromocytoma or insulinoma. - Store the kit according to manufacturer instructions, protecting from light and extreme temperatures.

Glucagen Hypokit can interact with certain medications or clinical conditions; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concurrent use of beta‑blockers that may mask typical glucagon side effects. - Administration with other agents that cause hyperglycemia, such as high‑dose corticosteroids, without monitoring. - Concomitant use of somatostatin analogues, which may blunt glucagon’s effect.

Use with caution: - Patients receiving oral hypoglycemic agents; monitor for rebound hypoglycemia after glucagon effect wanes. - Individuals on monoamine oxidase inhibitors; observe for potential cardiovascular effects. - Use in patients with known hypersensitivity to glucagon or kit components. - Patients with renal or hepatic impairment; dose may need adjustment. - Patients with cardiovascular disease; monitor hemodynamic response.